[Presentation] IMPACCT: Real World Evidence–The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan
[Presentation] IMPACCT: Real World Evidence--The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan by Cathy [...]
[Presentation] IMPACCT: Real World Evidence–Lessons Learned From The Development And Implementation of an Integrated Data And Evidence Strategy
IMPACCT: Real World Evidence--Lessons Learned From The Development And Implementation of an Integrated Data And Evidence Strategy by Tony Hebden [...]
Cost-Sharing Waivers for COVID-19 Treatment Are Expiring
Cost-sharing waivers for COVID-19 treatment are due to expire in the upcoming months. Approximately 88% in individual and fully insured [...]
[Webinar] Value Assessment in the Age of COVID-19: Meeting the Challenges
An important discussion is developing around Value Assessment (VA) and Health Technology Assessment (HTA) as COVID-19 intensifies challenges to effectively [...]
Teva Pharmaceuticals Stock Plunges 15.4%
Teva Pharmaceutical stands accused of defrauding Medicare using a kickback scheme to boost sales of Copaxone, prompting the US government [...]
[Video Chat] A Pandemic Means Society Needs Information Fast. Can Researchers Provide It?
Don't miss Stat's upcoming video chat on Thursday, Sept. 17 at 1 p.m. ET / 10 a.m. PT: Getting real [...]
[PODCAST] Open Access: Opportunities and Challenges
As the principles of open science become more widely adopted, open access publishing is an increasingly debated topic. Join International [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers [...]
How is Patient-Centered Outcomes Research Institute (PCORI) Contributing to The Fight Against COVID-19?
In response to the COVID-19 pandemic, the Patient-Centered Outcomes Research Institute (PCORI) has approved over $20 million in funding for [...]
Highmark and UCB Partner on Outcomes-based Contract for CIMZIA
Highmark has entered an outcomes-based agreement with UCB, Inc. for CIMZIA® (certolizumab pegol), UCB’s tumor necrosis factor blocker prescribed for [...]
Study Finds That Less Than 20% of Medicare Spending is Value-based
Boston-based health insurance company Coverys found that less than 20% of Medicare spending is value-based. In order to meet future [...]
How Are the U.S. Postal Service’s Woes Affecting Prescriptions?
There is increasing concern among physicians and policymakers that uncertainty concerning the fate of the U.S. Postal Service could delay [...]
How Can Chief Outcomes Officers Transform the C-Suite?
Improving outcomes, lowering costs, and increasing satisfaction are universal goals that few health care organizations or consumers feel they have [...]
Pharma14 adds South Korea to Global Medicine and Pricing Database
The pharmaceutical market in South Korea is undergoing rapid expansion and expected to reach more than US$ 21 billion by [...]
The Professional Society for Health Economics and Outcomes Research (ISPOR) Now Offers Renowned Short Course Program Virtually
ISPOR’s is offering the following virtual courses through its renowned short course program: September [...]
Course offering: Introduction to Medical Affairs in Medicines Development
Don’t miss out on this exciting new course covering the fundamentals of Medicines Development and how Medical Affairs functions bring [...]
How Does Consolidation Drive Prices?
Why do Americans spend so much on healthcare? According to a recent literature review, part of the reason may be [...]
Kamala Harris Is No Friend to Pharma
Vice presidential nominee Kamala Harris is not exactly the centrist the media are making her out to be—especially when it [...]
Towards a Better Understanding of Outcome-Based Contracts
Outcome-based contracting is an operational model that requires an ironclad relationship between customer and provider that provides the trust necessary [...]
Although COVID-19 has Dampened Pharma Sales in 2020, Outlook to 2026 is still Optimistic
According to the EvaluatePharma World Preview 2020, Outlook to 2026 report, COVID-19 has reduced biopharma sales forecasts by $7.85bn with [...]
The Most Expensive Drugs in the U.S. According to GoodRx
GoodRx has released its latest list of the most expensive drugs in America, with orphan drugs and therapies for rare [...]
Proposed change to CMS Rules Aim Will Expand Access to High-cost Therapies for Medicaid Recipients
The Medicaid Best Price rule requires drug manufacturers to give Medicaid the best price on all purchases. However, the rule [...]
How COVID-19 Provides Opportunities to Implement Value-Based Care Practices
COVID-19 has drastically changed the healthcare landscape for payers and providers as telehealth services are increasingly utilized. Experts discussed how [...]
Webinar Recap: It’s Time to Talk About COVID-19 Prices
Join National Pharmaceutical Council Chief Science Officer Robert Dubois, Memorial Sloan Kettering Cancer Center's Peter Bach, Institute for Clinical and [...]
Value-based Models Achieve Better Patient Outcomes in Primary Care Practices
A new study from United Health Group shows that primary care physicians (PCPs) perform better on key quality metrics when [...]